Libtayo for Treatment of Advanced Basal Cell Carcinoma

MedMaven

by Dr. C.H. Weaver M.D. 9/2020

The PD-1 inhibitor Libtayo® (cemiplimab) appears promising in for the treatment of patients with locally advanced basal cell carcinoma (BCC) that have previously progressed on or were intolerant to hedgehog inhibitor (HHI) therapy according to the results of a study presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. (1)

About Basal Cell Carcinoma

Basal cell carcinoma consists of abnormal, uncontrolled growths or lesions that arise in the skin’s basal cells, which line the deepest layer of the outermost layer of the skin. BCC accounts for more than 80% of non-melanoma skin cancers. It occurs most frequently on the head and neck, with the nose being the most common site. BCC that spreads from where it started to nearby tissue is called locally advanced disease and can be highly disfiguring.

While BCC is generally diagnosed and treated early, it may recur in an estimated 3% of patients after five years. Although BCC rarely becomes advanced, there have been few treatment options at this stage of the disease until the recent development of “hedgehog inhibitors”.(2-9)

About Libtayo

Libtayo is a fully human monoclonal antibody targeting the programmed death receptor-1 (PD-1) on T cells. Libtayo blocks the PD-1 protein that interferes with certain types of immune responses and may enhance the ability of the immune system to fight cancer. Libtayo is approved to treat patients with metastatic cutaneous squamous cell carcinoma (CSCC) or local advanced CSCC patients who are eligible for curative surgery or radiation.

About the Pivotal BCC trial

In the current trial patients with either locally advanced BCC and metastatic BCC were treated with Libtayo 350 mg intravenously every three weeks for up to 93 weeks or until disease progression. Overall 31% of patients responded to treatment with a median follow-up of 15 months. This included a 6% complete and 25% partial response rate. Responses were seen regardless of baseline PD-L1 expression in tumor cells. As of data cut-off, the median duration of response and median overall survival had not yet been reached. At one-year, 85% of responses were ongoing.

References

  1. Dummer R, Midgen M, Guminski A, et al. Efficacy and safety of sonidegib in patients with locally advanced or metastatic basal cell carcinoma: BOLT 30-month analysis. Presented at 2016 annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, June 4, 2016, poster #9538.
  2. news.cancerconnect.com/food-and-drug-administration-approves-odomzo-for-treatment-of-basal-cell-carcinoma-2/
  3. Cleveland Clinic. “Nonmelanoma Skin Cancer.” Available here
  4. National Cancer Institute. NCI Dictionary of Cancer Terms “locally advanced cancer.” Available here
  5. Danial C, Lingala B, Balise R, Oro AE, Reddy S, Colevas A, Chang AL. Markedly improved overall survival in 10 consecutive metastatic basal cell carcinoma patients. Br J Dermatol 2013: 1365-2133.
  6. Soleymani AD, Scheinfeld N, Vasil K, Bechtel MA. Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread. J Am Acad Dermatol. 2008;59(2 suppl 1):s1-s3.
  7. Moser S, Borm J, Mihic-Probst D, Jacobsen C, Kruse Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013.
  8. Chren MM, Linos E, Torres JS, Stuart SE, Parvataeni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol.2013;133:1188-96.
  9. Wong C S M, Strange R C, Lear J T. Basal cell carcinoma. BMJ. 2003; 327:794-798.